CG Oncology posts investor deck highlighting cretostimogene data in non-muscle invasive bladder cancer trials

CG Oncology, Inc.

CG Oncology, Inc.

CGON

0.00
  • CG Oncology highlighted updated efficacy for cretostimogene in high-risk BCG-unresponsive NMIBC across ongoing BOND-003 Phase 3 cohorts.
  • Cohort C (CIS only) showed 75.5% complete response at any time; 46.4% at 12 months; 41.8% at 24 months.
  • Cohort P (high-grade Ta/T1) reported high-grade event-free survival of 95.7% at 3 months; 84.6% at 6 months; 80.4% at 9 months.
  • Safety profile emphasized no grade 3 or higher treatment-related adverse events or deaths; most adverse events were grade 1-2.
  • Manufacturing capacity cited at 40,000-50,000 vials per year; scale-up work underway to support potential broader indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.